TY - JOUR
T1 - Diagnosis of non-celiac gluten sensitivity (NCGS)
T2 - The salerno experts’ criteria
AU - Catassi, Carlo
AU - Elli, Luca
AU - Bonaz, Bruno
AU - Bouma, Gerd
AU - Carroccio, Antonio
AU - Castillejo, Gemma
AU - Cellier, Christophe
AU - Cristofori, Fernanda
AU - de Magistris, Laura
AU - Dolinsek, Jernej
AU - Dieterich, Walburga
AU - Francavilla, Ruggiero
AU - Hadjivassiliou, Marios
AU - Holtmeier, Wolfgang
AU - Körner, Ute
AU - Leffler, Dan A.
AU - Lundin, Knut E.A.
AU - Mazzarella, Giuseppe
AU - Mulder, Chris J.
AU - Pellegrini, Nicoletta
AU - Rostami, Kamran
AU - Sanders, David
AU - Skodje, Gry Irene
AU - Schuppan, Detlef
AU - Ullrich, Reiner
AU - Volta, Umberto
AU - Williams, Marianne
AU - Zevallos, Victor F.
AU - Zopf, Yurdagül
AU - Fasano, Alessio
N1 - Publisher Copyright:
© 2015 by the authors; licensee MDPI, Basel, Switzerland.
PY - 2015/6/18
Y1 - 2015/6/18
N2 - Non-Celiac Gluten Sensitivity (NCGS) is a syndrome characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing food, in subjects that are not affected by either celiac disease or wheat allergy. Given the lack of a NCGS biomarker, there is the need for standardizing the procedure leading to the diagnosis confirmation. In this paper we report experts’ recommendations on how the diagnostic protocol should be performed for the confirmation of NCGS. A full diagnostic procedure should assess the clinical response to the gluten-free diet (GFD) and measure the effect of a gluten challenge after a period of treatment with the GFD. The clinical evaluation is performed using a self-administered instrument incorporating a modified version of the Gastrointestinal Symptom Rating Scale. The patient identifies one to three main symptoms that are quantitatively assessed using a Numerical Rating Scale with a score ranging from 1 to 10. The double-blind placebo-controlled gluten challenge (8 g/day) includes a one-week challenge followed by a one-week washout of strict GFD and by the crossover to the second one-week challenge. The vehicle should contain cooked, homogeneously distributed gluten. At least a variation of 30% of one to three main symptoms between the gluten and the placebo challenge should be detected to discriminate a positive from a negative result. The guidelines provided in this paper will help the clinician to reach a firm and positive diagnosis of NCGS and facilitate the comparisons of different studies, if adopted internationally.
AB - Non-Celiac Gluten Sensitivity (NCGS) is a syndrome characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing food, in subjects that are not affected by either celiac disease or wheat allergy. Given the lack of a NCGS biomarker, there is the need for standardizing the procedure leading to the diagnosis confirmation. In this paper we report experts’ recommendations on how the diagnostic protocol should be performed for the confirmation of NCGS. A full diagnostic procedure should assess the clinical response to the gluten-free diet (GFD) and measure the effect of a gluten challenge after a period of treatment with the GFD. The clinical evaluation is performed using a self-administered instrument incorporating a modified version of the Gastrointestinal Symptom Rating Scale. The patient identifies one to three main symptoms that are quantitatively assessed using a Numerical Rating Scale with a score ranging from 1 to 10. The double-blind placebo-controlled gluten challenge (8 g/day) includes a one-week challenge followed by a one-week washout of strict GFD and by the crossover to the second one-week challenge. The vehicle should contain cooked, homogeneously distributed gluten. At least a variation of 30% of one to three main symptoms between the gluten and the placebo challenge should be detected to discriminate a positive from a negative result. The guidelines provided in this paper will help the clinician to reach a firm and positive diagnosis of NCGS and facilitate the comparisons of different studies, if adopted internationally.
KW - Diagnosis
KW - Double-blind placebo-controlled challenge
KW - Gastrointestinal symptom rating scale
KW - Irritable bowel syndrome
KW - Non-celiac gluten sensitivity
UR - http://www.scopus.com/inward/record.url?scp=84935007319&partnerID=8YFLogxK
U2 - 10.3390/nu7064966
DO - 10.3390/nu7064966
M3 - Journal article
C2 - 26096570
AN - SCOPUS:84935007319
SN - 2072-6643
VL - 7
SP - 4966
EP - 4977
JO - Nutrients
JF - Nutrients
IS - 6
ER -